Cabaletta Bio is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. The company utilizes its proprietary Cabaletta Approach to B cell Ablation (CABA) platform, which employs the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) strategy to transiently eliminate B cells and reset the immune system. Its lead product candidate, resecabtagene autoleucel (rese-cel), is a fully human CD19-CAR T cell therapy designed for a one-time administration to treat conditions such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Cabaletta Bio is conducting Phase 1/2 clinical trials under the RESET program, including registrational cohorts for dermatomyositis and anti-synthetase syndrome. The company partners with Contract and Development Manufacturing Organizations (CDMOs) and utilizes the Cellares Cell Shuttle automated manufacturing platform to scale production. Founded in 2017 and emerging from the University of Pennsylvania, Cabaletta Bio targets patients with B cell-mediated autoimmune diseases who have high unmet medical needs.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage cabalettabio.com
Sector Healthcare IR page cabalettabio.com/investors
Tags
cell therapy, car t cells, autoimmune diseases, b cell ablation, systemic lupus erythematosus, myositis, systemic sclerosis, myasthenia gravis, pemphigus vulgaris, immune system reset, CABA, CARTA, rese-cel, resecabtagene autoleucel, CABA-201, RESET-Myositis, RESET-SLE, RESET-SSc, Cell Shuttle, Cellares
Press page cabalettabio.com/investors/news-events/press-releases

Metrics

Valuation  
Market cap $ 414.183M
Market cap (USD) $ 414.183M
P/E -1.56
PEG —
P/BV 1.46
P/S —
P/OCF -2.55
P/FCF -2.55
Dividend yield —
Turnover / mcap —
Returns  
ROE -127.0%
ROI -525.4%
ROIC -404.3%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 40
Quality score -63.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Assets 165.083M 185.046M 253.65M 116.968M 126.336M 114.724M 141.468M 34.174M
Net profit -167.856M -115.864M -67.675M -52.975M -46.289M -33.339M -16.943M -12.202M
Free cash flow -132.309M -90.433M -54.236M -48.833M -35.275M -27.405M -16.738M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 2.19 2.27 22.7 9.25 3.79 12.48 13.97 —
Price performance 12m -0.04 -0.9 1.45 1.44 -0.7 -0.11 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 0.00 5.14M 5.02M 15.6M 27.1M
Cash and deposits (USD) 33M 136M 101M 122M 81.6M 193M 164M 83M
Right-of-use assets (USD) — — — 0.00 4.99M 4.91M 6.32M 3.43M
Cash flow detail
Operating cash flow (USD) -4.66M -16M -26.8M -34.1M -46.4M -53.5M -88.2M -131M
Purchases of property, plant and equipment (USD) — -693,000 -635,000 -1.17M -2.45M -687,000 -2.21M -1.23M
Change in payables (cash effect) (USD) 234,000 246,000 555,000 975,000 -28,000 1.68M 1.01M 1.55M
Interest paid (cash effect) (USD) — — — — — 0.00 -748,000 -1.71M
Share-based compensation (USD) 606,000 2.3M 4.39M 5.8M 6.9M 11.3M 19.5M 20.9M
Free cash flow (OCF - PPE - intangibles) (USD) — -16.7M -27.4M -35.3M -48.8M -54.2M -90.4M -132M
Income detail
Research and development expense (USD) 4.47M 11.7M 21.4M 32.5M 39.3M 55.4M 97.2M 143M
↳ 5y CAGR +65.5% +52.8% +46.2%
Total comprehensive income (USD) — -22.3M -33.3M -46.3M -53M -67.6M -116M -168M
Comprehensive income to owners (USD) — -22.3M -33.3M -46.3M -53M -67.6M -116M -168M
Reported Mar 30, 2020 Mar 16, 2021 Mar 16, 2021 Mar 16, 2023 Mar 16, 2023 Mar 31, 2025 Mar 31, 2025 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroids

100% (5 of 5) of lupus nephritis patients with follow-up from six months to two years achieved immunomodulator-free DORIS remission and evidence of little-to-no disease activity based on repeat kidney biopsies

71% (5 of 7) of systemic sclerosis patients achieved immunomodulator-free rCRISS-50 and the five patients with interstitial lung disease achieved 9% mean FVC improvement, both at one year

71-patient clinical experience with rese-cel following preconditioning reinforces favorable benefit-risk profile across myositis, systemic sclerosis, lupus, and myasthenia gravis

PHILADELPHIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc.

RESET-Myositis® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data

Immunomodulator-free durability data from the complete Phase 1/2 dermatomyositis cohort at one year and from the complete Phase 1/2 lupus nephritis cohort with follow-up as long as two years as well as updated safety data from the RESET™ program with preconditioning to be presented during ACR Convergence 2026

RESET-SSc® registrational cohort initiated in systemic sclerosis patients with interstitial lung disease including endpoints evaluating improvement of lung function and overall disease

PC-free program advancing with maturing data expected to inform 1H27 go-forward clinical development plans

Operational runway extended into 1Q28 with $299.4 million cash position as of September 30, 2026

PHILADELPHIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc.

IR Calendar

Upcoming Events

There are no upcoming events scheduled at this time. Sign up here to receive notices about upcoming events and press releases.

Past Events

Sep 16, 2026 8:30 am EDT

H.C. Wainwright 28th Annual Global Investment Conference

New York, NY

Sep 14, 2026 10:45 am EDT

Morgan Stanley 24th Annual Global Healthcare Conference


New York, NY

Audio

Webcast

Sep 9, 2026 8:35 am EDT

2026 Cantor Global Healthcare Conference


New York, NY

Audio

Webcast

Sep 8, 2026

Wells Fargo 21st Annual Healthcare Conference

Boston, MA

Jun 9, 2026 9:00 am EDT

2026 Annual Meeting of Stockholders


Audio

Webcast

Jun 8, 2026 10:00 am EDT

Goldman Sachs 47th Annual Global Healthcare Conference


Audio

Webcast

Jun 3, 2026 7:35 am EDT

Jefferies Global Healthcare Conference in New York


Audio

Webcast

Jun 3 – Jun 6, 2026

European Alliance of Associations for Rheumatology (EULAR) 2026 Congress

London, UK

May 19, 2026 4:00 pm EDT

H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ


Audio

Webcast

May 11 – May 15, 2026

American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Boston, MA

View All Past Events

Cabaletta Bio, Inc.

2929 Arch Street
Suite 600
Philadelphia, PA 19104

© 2026 Cabaletta Bio, Inc. All Rights Reserved.

Disclaimer Terms of Use Sitemap Privacy Notice HR Privacy Notice (EU)

Prompts

Cabaletta Bio, Inc. (ticker CABA), listed in United States.

ETFs Holding Cabaletta Bio, Inc.

ETF Weight in ETF Shares Market value As of
SURI 0.83% 556,235 $ 567.36K Nov 17, 2026
TMED 0.62% 45,659 $ 141.999K Jun 30, 2026
VFMO 0.08% 485,055 $ 1.509M Aug 31, 2026
FSEG 0.06% 1,138 $ 3,539.18 Jun 30, 2026
RESM 0.01% 167 $ 519.37 Jun 30, 2026
DFAS 0.00% 667,370 $ 887.602K Nov 12, 2026
DXUV 0.00% 15,719 $ 20.906K Nov 12, 2026
DFAU 0.00% 22,315 $ 29.679K Nov 12, 2026
DFAC 0.00% 93,977 $ 124.989K Nov 12, 2026
DFUS 0.00% 23,221 $ 30.884K Nov 12, 2026
DCOR 0.00% 22,529 $ 29.964K Nov 12, 2026
AVSC 0.00% 14,845 $ 16.478K Nov 16, 2026